396
views
0
recommends
+1 Recommend
0 collections
    1
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Fueling Open-Source Drug Discovery: 177 Small-Molecule Leads against Tuberculosis

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          With the aim of fuelling open-source, translational, early-stage drug discovery activities, the results of the recently completed antimycobacterial phenotypic screening campaign against Mycobacterium bovis BCG with hit confirmation in M. tuberculosis H37Rv were made publicly accessible. A set of 177 potent non-cytotoxic H37Rv hits was identified and will be made available to maximize the potential impact of the compounds toward a chemical genetics/proteomics exercise, while at the same time providing a plethora of potential starting points for new synthetic lead-generation activities. Two additional drug-discovery-relevant datasets are included: a) a drug-like property analysis reflecting the latest lead-like guidelines and b) an early lead-generation package of the most promising hits within the clusters identified.

          Related collections

          Most cited references32

          • Record: found
          • Abstract: not found
          • Article: not found

          Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25.1

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Drugs for bad bugs: confronting the challenges of antibacterial discovery.

            The sequencing of the first complete bacterial genome in 1995 heralded a new era of hope for antibacterial drug discoverers, who now had the tools to search entire genomes for new antibacterial targets. Several companies, including GlaxoSmithKline, moved back into the antibacterials area and embraced a genomics-derived, target-based approach to screen for new classes of drugs with novel modes of action. Here, we share our experience of evaluating more than 300 genes and 70 high-throughput screening campaigns over a period of 7 years, and look at what we learned and how that has influenced GlaxoSmithKline's antibacterials strategy going forward.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The exploration of macrocycles for drug discovery--an underexploited structural class.

              Macrocyclic natural products have evolved to fulfil numerous biochemical functions, and their profound pharmacological properties have led to their development as drugs. A macrocycle provides diverse functionality and stereochemical complexity in a conformationally pre-organized ring structure. This can result in high affinity and selectivity for protein targets, while preserving sufficient bioavailability to reach intracellular locations. Despite these valuable characteristics, and the proven success of more than 100 marketed macrocycle drugs derived from natural products, this structural class has been poorly explored within drug discovery. This is in part due to concerns about synthetic intractability and non-drug-like properties. This Review describes the growing body of data in favour of macrocyclic therapeutics, and demonstrates that this class of compounds can be both fully drug-like in its properties and readily prepared owing to recent advances in synthetic medicinal chemistry.
                Bookmark

                Author and article information

                Journal
                ChemMedChem
                ChemMedChem
                cmdc
                Chemmedchem
                WILEY-VCH Verlag (Weinheim )
                1860-7179
                1860-7187
                February 2013
                10 January 2013
                : 8
                : 2
                : 313-321
                Affiliations
                [[a] ]Tres Cantos Medicines Development Campus (TCMDC), GlaxoSmithKline (GSK) Severo Ochoa 2, Tres Cantos, Madrid (Spain)
                [[b] ]CSC Medicinal Chemistry, Medicines Research Centre, GlaxoSmithKline (GSK) Stevenage, Hertfordshire, SG1 2NY (UK)
                Author notes

                Supporting information for this article is available on the WWW under http://dx.doi.org/10.1002/cmdc.201200428.

                Re-use of this article is permitted in accordance with the Terms and Conditions set out at http://chemmedchem.org/open.

                Article
                10.1002/cmdc.201200428
                3743164
                23307663
                ca8e5dc7-96a2-4ed6-9cba-62ef9b714856
                Copyright © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim

                Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.

                History
                : 19 September 2012
                : 14 November 2012
                Categories
                Full Papers

                Pharmaceutical chemistry
                drug discovery,high-throughput screening,open innovation,tuberculosis
                Pharmaceutical chemistry
                drug discovery, high-throughput screening, open innovation, tuberculosis

                Comments

                Comment on this article